Biofrontera Inc. (BFRI)
$0.89-4.30%Close
SELLCRISIS · day 22
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $11M
- Beta
- 0.88
- P/E (TTM)
- -1.49
- Short % float
- 1.35%
- Days to cover
- 1.0
- SI change
- -68.4%
- 1W
- -4.30%
- 1M
- -34.56%
- vs SPY 1W
- -4.16%
- vs SPY 1M
- -37.06%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 49
- VALUE
- 23
- GROWTH
- 42
- GARP
- 87
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-76.7%
REV YoY-
ROE-127.8%
EPS YoY-
ROA-26.5%
GROSS84
OP-9
NET-14
[VALUATION]
P/E TTM-1.49
P/E FWD5.05
SECTOR PE20.34
INDUSTRY PE104.65
P/B1.94
P/FCF-
EV/EBITDA-2.63
EV/EBIT-
PEG0.12
FCF YIELD-
RISK
INT COV-
D/E125.99
ALTMAN Z-
CURR RATIO1.18
ND/EBITDA-
BETA0.88
Company news
FAQ
- What is LOPJLB’s current signal on BFRI?
- LOPJLB’s latest quantitative signal on Biofrontera Inc. (BFRI) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is BFRI in?
- Biofrontera Inc. (BFRI) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Biofrontera Inc. (BFRI) do?
- Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquar…